Olympus to sell scientific instruments business to Bain Capital
Torys is acting as Canadian counsel to Olympus with a team that includes Don Bell, Guillaume Lavoie and Ana Ioanas (corporate/M&A), Courtney Barbour, Nicole Baker and Nathan Little (due diligence), Ed Fan, Sue Fei and Michele Clarizio (IP), Cristelle Sary and Christophe Cinqmars-Viau (employment), Michael Fortier (environmental), Molly Reynolds (privacy) and Omar Wakil (competition).
On August 29, 2022, Olympus Corporation (“Olympus”) and EVIDENT Corporation ("EVIDENT"), a wholly-owned subsidiary of Olympus, announced a definitive agreement with Bain Capital Private Equity, LP (“Bain Capital”) pursuant to which Olympus will transfer all shares of EVIDENT to Bain Capital for ¥427.6 billion yen (US$3.1 billion).
The transfer it is expected to take place on January 4, 2023, subject to regulatory approvals and closing conditions.
Further information can be found on Olympus’ website.
EVIDENT (formerly Olympus' Scientific Solutions Division) develops, manufactures, sells and provides solutions for biological and industrial microscopes, industrial videoscopes and fiberscopes, non-destructive testing equipment, and X-ray analyzers.
Bain Capital is one of the world’s leading private investment firms with approximately US$160 billion in assets under management.
Olympus, a leading manufacturer of optical and digital precision technology, is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries.